JiangXi Tianxin Pharm Co Ltd
JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as i… Read more
JiangXi Tianxin Pharm Co Ltd (603235) - Net Assets
Latest net assets as of June 2025: CN¥4.68 Billion CNY
Based on the latest financial reports, JiangXi Tianxin Pharm Co Ltd (603235) has net assets worth CN¥4.68 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.75 Billion) and total liabilities (CN¥1.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.68 Billion |
| % of Total Assets | 81.34% |
| Annual Growth Rate | 41.39% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44.44 |
JiangXi Tianxin Pharm Co Ltd - Net Assets Trend (2020–2024)
This chart illustrates how JiangXi Tianxin Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for JiangXi Tianxin Pharm Co Ltd (2020–2024)
The table below shows the annual net assets of JiangXi Tianxin Pharm Co Ltd from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.62 Billion | +9.05% |
| 2023-12-31 | CN¥4.23 Billion | +4.31% |
| 2022-12-31 | CN¥4.06 Billion | +112.60% |
| 2021-12-31 | CN¥1.91 Billion | +65.27% |
| 2020-12-31 | CN¥1.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to JiangXi Tianxin Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2420.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.02 Billion | 43.81% |
| Other Components | CN¥2.59 Billion | 56.19% |
| Total Equity | CN¥4.62 Billion | 100.00% |
JiangXi Tianxin Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of JiangXi Tianxin Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GeoPark Limited
SA:GPRK34
|
$158.72 Million |
|
Anji Foodstuff Co Ltd
SHG:603696
|
$158.74 Million |
|
Verano Holdings Corp
OTCQX:VRNOF
|
$158.75 Million |
|
Nanjing TDH Technology Co. Ltd. A
SHE:301378
|
$158.81 Million |
|
Paisalo Digital Limited
NSE:PAISALO
|
$158.57 Million |
|
OK Science & Technology Co. Ltd. A
SHE:001223
|
$158.53 Million |
|
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
|
$158.53 Million |
|
IDI S.C.A.
PA:IDIP
|
$158.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in JiangXi Tianxin Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,232,947,161 to 4,615,885,977, a change of 382,938,816 (9.0%).
- Net income of 651,223,140 contributed positively to equity growth.
- Dividend payments of 220,188,547 reduced retained earnings.
- Other factors decreased equity by 48,095,777.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥651.22 Million | +14.11% |
| Dividends Paid | CN¥220.19 Million | -4.77% |
| Other Changes | CN¥-48.10 Million | -1.04% |
| Total Change | CN¥- | 9.05% |
Book Value vs Market Value Analysis
This analysis compares JiangXi Tianxin Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.64x to 2.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥2.93 | CN¥28.27 | x |
| 2021-12-31 | CN¥4.84 | CN¥28.27 | x |
| 2022-12-31 | CN¥9.27 | CN¥28.27 | x |
| 2023-12-31 | CN¥9.67 | CN¥28.27 | x |
| 2024-12-31 | CN¥10.54 | CN¥28.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently JiangXi Tianxin Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.11%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.49%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.21x
- Recent ROE (14.11%) is below the historical average (31.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 76.81% | 38.51% | 0.79x | 2.52x | CN¥771.60 Million |
| 2021 | 38.97% | 29.49% | 0.85x | 1.55x | CN¥553.02 Million |
| 2022 | 15.33% | 26.99% | 0.49x | 1.15x | CN¥216.32 Million |
| 2023 | 11.24% | 25.28% | 0.37x | 1.20x | CN¥52.56 Million |
| 2024 | 14.11% | 29.49% | 0.39x | 1.21x | CN¥189.63 Million |
Industry Comparison
This section compares JiangXi Tianxin Pharm Co Ltd's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $2,496,572,190
- Average return on equity (ROE) among peers: -3.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| JiangXi Tianxin Pharm Co Ltd (603235) | CN¥4.68 Billion | 76.81% | 0.23x | $158.63 Million |
| Xiwang Foodstuffs Co Ltd (000639) | $65.61 Million | -62.17% | 1.91x | $345.26 Million |
| Nanfang Black Sesame Group Co Ltd (000716) | $199.49 Million | -32.62% | 2.81x | $346.21 Million |
| CNFC Overseas Fishery Co Ltd (000798) | $727.64 Million | 8.49% | 0.27x | $430.25 Million |
| Henan Shuanghui Investment & Development Co Ltd (000895) | $16.36 Billion | 24.69% | 0.34x | $3.98 Billion |
| Xinjiang Chalkis Co Ltd (000972) | $760.28 Million | -33.42% | 2.17x | $202.97 Million |
| Zhengzhou Qianweiyangchu Food Co Ltd (001215) | $332.95 Million | 17.62% | 0.88x | $266.09 Million |
| Wenzhou Yuanfei Pet Toy Products Co. Ltd. A (001222) | $1.35 Billion | 9.31% | 0.15x | $160.97 Million |
| Guangdong Yuehai Feeds Group Co.Ltd. (001313) | $2.07 Billion | 7.87% | 0.47x | $169.20 Million |
| Shandong Oriental Ocean Sci-Tech Co Ltd (002086) | $393.72 Million | 8.08% | 0.70x | $460.31 Million |
| Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd (002100) | $2.70 Billion | 14.52% | 0.66x | $903.18 Million |